SOLICITATION NOTICE
B -- Tissue bank Pathology Service
- Notice Date
- 9/4/2003
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- Reference-Number-NCI-30144-NV
- Response Due
- 9/19/2003
- Archive Date
- 10/4/2003
- Point of Contact
- Deborah Moore, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Renita Smith, Contract Specialist, Phone 301-496-8612, Fax 301-480-0241,
- E-Mail Address
-
dm170b@nih.gov, rs442i@nih.gov
- Description
- The National Cancer Institute (NCI), Division of Cancer Treatment and Diagnosis (DCTD), Cancer Diagnosis Program (CDP) plans to procure on a sole souce basis with University of Michigan Medical School, Dana Farber Cancer Institute and Memorial Sloan Kettering Cancer Center to obtain one-time access to early stage lung adenocarcinoma specimens and their associated clinical data to be analyzed in a lung profile confirmation study. The Cancer Diagnosis Program has overall responsibility for planning, evaluation and coordination of NCI research related to cancer diagnostics. Lung Cancer is the most frequent cause of cancer deaths in the United States. Up to 40% of “early stage” lung cancer patients will die of the disease. Three projects in the Director’s Challenge initiative have reported gene expression profiles that identify clinical subsets of stage I lung adenocarcinoma patients. Each research group has identified a subset of patients with a significantly worse outcome than the majority of stage I patients. These molecular profiles are particularly promising since all three academic groups used different analytical platforms and used different criteria for the selection of specimens for analysis. This information is of great clinical importance because it has the potential to identify patients who will be cured by surgery alone, as well as those for whom improved therapy needs to be developed. Although this data is exciting, it needs to be confirmed on a larger set of tumors using standardized protocols which is the purpose of this procurement. The work to be performed under this contract requires access to early stage lung adenocarcinoma obtained from patients with the appropriately documented clinical follow-up as well as appropriately standardized and documented surgical procedures. These specific specimens are needed to confirm the diagnostic utility of gene expression signatures for predicting outcome after surgery for early stage lung adenocarcinoma. There are very few large collections of frozen specimens that meet these criteria. The investigators involved in this study were identified as having the required frozen tumors, expert clinicians and pathologists, and access to expert gene expression analysis, statistical analysis and appropriate database support. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can perform this requirement. An original and one copy of the capability statements must be received in the contracting office by 1:00 p.m. EDT, on September 19, 2003. All questions must be in writing and can be faxed to (301) 402-4513 or emailed to dm170b@nih.gov . It is the vendor’s responsibility to call (301) 402-4509 to insure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect call will be accepted.
- Web Link
-
Link to FedBizOpps document.
(http://www.eps.gov/spg/HHS/NIH/RCB/Reference-Number-NCI-30144-NV/listing.html)
- Record
- SN00426337-F 20030906/030904214029 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |